American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18.
Ashina M. Efficacy, clinically meaningful responses, and impact on acute headache medication use with fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study. Presented at: the 13th European Headache Federation Congress; Athens, Greece; May 30, 2019.
Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999-2008.
Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39:445-458.
Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies -- successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338-350.
European Medicines Agency. Aimovig® (erenumab) Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig. Accessed June 12, 2019.
European Medicines Agency. Ajovy® (fremanezumab) Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy. Accessed June 12, 2019.
European Medicines Agency. Emgality® (galcanezumab) Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/emgality. Accessed June 12, 2019.
Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132.
Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470-485.
Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:788-790.
Melo-Carrillo A, Noseda R, Nir RR, et al. Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci. 2017;37:7149-7163.
Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab-a humanized monoclonal anti-cgrp antibody-inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017;37:10587-10596.
Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013;154(suppl 1):S44-53.
Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280-2287.
Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6.
Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013;93:78-85.
Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080-1088.
Steiner TJ, Antonaci F, Jensen R, et al. Recommendations for headache service organisation and delivery in Europe. J Headache Pain. 2011;12:419-426.
Steiner TJ, Jensen R, Dr Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20:57.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Messoud Ashina, MD, PhD, DMSc

Professor of Neurology
Department of Neurology
University of Copenhagen
Danish Headache Center
Neuroscience Center
Copenhagen, Denmark

Disclosures

Disclosure: Messoud Ashina, MD, PhD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alder Biopharmaceuticals, Inc.; Amgen, Inc. ; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva

Panelists

Rami Burstein, PhD

Professor of Anesthesia and Neuroscience
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Rami Burstein, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alder BioPharmaceuticals Inc; Allergan, Inc.; Automated Technologies, Inc.; Avanir Pharmaceuticals, Inc.; Depomed, Inc; Dr. Reddy's Laboratories Ltd Electrocore; Percept Pharma Services, Inc; Pernix Therapeutics; Strategic Science & Technologies; Teva Pharmaceuticals USA; Trigemina, Inc.
Received grants for clinical research from: Allergan, Inc.; Depomed, Inc.; Dr. Reddy's Laboratories Ltd; Myelin Repair Foundation; Strategic Science & Technologies; Teva Pharmaceuticals USA; Trigemina, Inc.

Dr Burstein does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Burstein does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Zaza Katsarava, MD, PhD

Chief, Department of Neurology
Evangelical Hospital Unna
Professor of Neurology
University of Essen
Essen, Germany

Disclosures

Disclosure: Zaza Katsarava, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; StreamUP; Teva
Received grants for clinical research from: Allergan, Inc.; Novartis Pharmaceuticals Corporation

Patricia Pozo-Rosich, MD, PhD

Head, Headache and Craniofacial Pain Unit
Vall d'Hebron University Hospital
Barcelona, Spain

Disclosures

Disclosure: Patricia Pozo-Rosich, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Almirall Hermal GmbH; Amgen, Inc.; Chiesi Farmaceutici SpA; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Almirall Hermal GmbH; Chiesi Farmaceutici SpA; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
Received grants for clinical research from: Allergan, Inc.

Editor

Leanne Fairley, BJ Hon

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Leanne Fairley, BJ Hon, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CPD

A New Era in Migraine Prevention

Authors: Messoud Ashina, MD, PhD, DMSc; Rami Burstein, PhD; Zaza Katsarava, MD, PhD; Patricia Pozo-Rosich, MD, PhD
CPD Released: 6/25/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/25/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an audience of European neurologists and primary care physicians.

The goal of this activity is to improve physician awareness of the science of calcitonin gene-related peptide (CGRP) in migraine prevention, key data on monoclonal antibodies (mAbs) targeting CGRP, and clinical implications of these novel treatments.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Benefits and limitations of currently available therapies for migraine prevention
- Mechanism of action of novel therapies in development for migraine prevention
- Latest efficacy and tolerability data for episodic and chronic migraine prevention therapies

Disclosures

Moderator

Messoud Ashina, MD, PhD, DMSc

Professor of Neurology
Department of Neurology
University of Copenhagen
Danish Headache Center
Neuroscience Center
Copenhagen, Denmark

Disclosures

Disclosure: Messoud Ashina, MD, PhD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alder Biopharmaceuticals, Inc.; Amgen, Inc. ; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva

Panelists

Rami Burstein, PhD

Professor of Anesthesia and Neuroscience
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Rami Burstein, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alder BioPharmaceuticals Inc; Allergan, Inc.; Automated Technologies, Inc.; Avanir Pharmaceuticals, Inc.; Depomed, Inc; Dr. Reddy's Laboratories Ltd Electrocore; Percept Pharma Services, Inc; Pernix Therapeutics; Strategic Science & Technologies; Teva Pharmaceuticals USA; Trigemina, Inc.
Received grants for clinical research from: Allergan, Inc.; Depomed, Inc.; Dr. Reddy's Laboratories Ltd; Myelin Repair Foundation; Strategic Science & Technologies; Teva Pharmaceuticals USA; Trigemina, Inc.

Dr Burstein does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Burstein does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Zaza Katsarava, MD, PhD

Chief, Department of Neurology
Evangelical Hospital Unna
Professor of Neurology
University of Essen
Essen, Germany

Disclosures

Disclosure: Zaza Katsarava, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; StreamUP; Teva
Received grants for clinical research from: Allergan, Inc.; Novartis Pharmaceuticals Corporation

Patricia Pozo-Rosich, MD, PhD

Head, Headache and Craniofacial Pain Unit
Vall d'Hebron University Hospital
Barcelona, Spain

Disclosures

Disclosure: Patricia Pozo-Rosich, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan, Inc.; Almirall Hermal GmbH; Amgen, Inc.; Chiesi Farmaceutici SpA; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Almirall Hermal GmbH; Chiesi Farmaceutici SpA; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
Received grants for clinical research from: Allergan, Inc.

Editor

Leanne Fairley, BJ Hon

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Leanne Fairley, BJ Hon, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

Educational Impact Challenge

What did you learn from this activity? Please click on the "Next" button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.

« Back

Page 2 of 4

Educational Impact Challenge

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

References

Faculty and Disclosures

Moderator

Messoud Ashina, MD, PhD, DMSc

Panelists

Rami Burstein, PhD

Zaza Katsarava, MD, PhD

Patricia Pozo-Rosich, MD, PhD

Editor

Leanne Fairley, BJ Hon

Content Reviewer

Nafeez Zawahir, MD

CPD

A New Era in Migraine Prevention

Target Audience and Goal Statement

Disclosures

Moderator

Messoud Ashina, MD, PhD, DMSc

Panelists

Rami Burstein, PhD

Zaza Katsarava, MD, PhD

Patricia Pozo-Rosich, MD, PhD

Editor

Leanne Fairley, BJ Hon

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

A New Era in Migraine Prevention

Educational Impact Challenge